The FDA rarely refuses to consider an application for a new drug or vaccine, but that’s what Dr. Prasad did last week in a move that shocked the industry. He said Moderna’s late-stage trial wasn’t “adequate and well-controlled” because the control arm did not reflect the “best-available standard of care,” which he deemed a high-dose flu vaccine.